Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjogren's Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients

Simon Bowman, Robert Fox, Thomas Doerner, Xavier Mariette, Athena Papas, Thomas Grader-Beck, Benjamin A. Fisher, Filipe Barcelos, Salvatore De Vita, Hendrik Schulze-Koops, Robert J. Moots, Guido Junge, Janice Woznicki, Monika Sopala, Wen-Lin Luo, Wolfgang Hueber

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
JournalArthritis & rheumatology
Publication statusPublished - Oct 2019

Cite this